DoD Melanoma, Idea Award | W81XWH 20 MRP IA

DoD Melanoma, Idea Award (FY20 MRP Idea Award) - FAQs

What is the DoD Melanoma, Idea Award (FY20 MRP Idea Award)?

The DoD Melanoma, Idea Award (FY20 MRP Idea Award) is a Department of Defense research funding opportunity intended to spark genuinely new directions in melanoma research. It is specifically focused on innovative, untested, high-risk ideas with the potential for high-reward impact if successful.

What is the primary purpose of this award?

The core purpose is to move the melanoma research field forward by encouraging concepts, theories, paradigms, and methods that are not simple extensions of existing work. The program is designed to open fresh lines of investigation rather than fund incremental progress along established trajectories.

Why does the DoD fund melanoma research through this program?

The opportunity emphasizes relevance to the military context: improving melanoma knowledge, patient care, and treatment options within the Military Health System can directly benefit active duty Service members, Veterans, and other military beneficiaries, while also translating to broader public health impact.

What kind of research is this award trying to support?

This award aims to support projects that are innovative and untested, especially those that are high-risk but could produce high-reward outcomes. Competitive projects are expected to introduce a new paradigm, challenge an existing paradigm, or reframe a persistent problem from a distinctly new perspective.

Is this award meant for speculative brainstorming, or does it require a concrete plan?

It is not intended for speculative brainstorming alone. A central requirement is that the application proposes a well-formulated, testable novel hypothesis supported by strong scientific reasoning and a solid study design that can realistically generate interpretable results.

What is required in the application in terms of hypothesis and study design?

The program requires a novel, testable hypothesis along with strong scientific reasoning and a rigorous study design. The emphasis is on having a clear scientific question and an approach that can produce interpretable findings, even if the idea itself is bold and high-risk.

How does the program define "innovation" for this award?

Innovation is the defining feature of this award. The program looks for research that meaningfully departs from standard melanoma research trajectories by introducing a new paradigm, challenging an established one, or offering a distinctly new way to view and test a difficult problem.

What types of projects are explicitly not considered innovative under this opportunity?

The announcement indicates that the following are not considered innovation: incremental advances, the next obvious step in a known line of work, and simply transferring an approach from another cancer type to melanoma without a compelling and creative rationale.

Can I apply with a project that extends my existing melanoma research?

The award explicitly avoids funding work that represents a logical continuation of an established research project. The intent is to discourage repackaging ongoing research as "new" and instead prioritize ideas that would not typically be funded through more conservative mechanisms.

If my idea is high-risk, how do I make it fit the program expectations?

The program is designed to support high-risk ideas, but it still expects strong scientific reasoning, a well-formulated testable hypothesis, and a solid study design. The key is showing that the risk is justified by the potential payoff and that the plan can generate interpretable results.

Who is the issuing agency for this funding opportunity?

The opportunity was offered by the Department of Defense, Department of the Army, through USAMRAA.

What is the Funding Opportunity Number for this award?

The Funding Opportunity Number is W81XWH-20-MRP-IA.

What activity category is associated with this opportunity?

It falls under the Science and Technology and other Research and Development activity category.

What CFDA number is associated with this program?

The opportunity is associated with CFDA 12.420.

Is this opportunity discretionary or mandatory?

The opportunity is listed as discretionary.

What funding mechanisms are supported (grant vs. cooperative agreement)?

The opportunity supports funding through either grants or cooperative agreements. This typically indicates that awards may range from standard grant-like support to a mechanism that could involve more agency participation, depending on which mechanism is used.

Who is eligible to apply?

Eligibility is described as unrestricted, meaning it is broadly open to many entity types, subject to any additional eligibility clarifications that may exist in the full announcement.

When was this opportunity posted?

The posting date was April 21, 2020.

What was the original closing date for applications?

The original closing date was September 24, 2020.

How many awards were anticipated?

The program anticipated making about 9 awards.

What is the maximum award amount (award ceiling)?

In the provided record, the award ceiling is shown as 0. This usually indicates that applicants must consult the full funding announcement for the actual maximum award amount or that the ceiling was not captured in the summary field.

What is the overall takeaway for applicants considering this award?

This award is best understood as a catalyst for bold melanoma research concepts. It rewards originality, requires a testable hypothesis and rigorous design, and is intentionally structured to avoid funding projects that merely continue existing work. The goal is to create new research avenues that could ultimately improve melanoma outcomes in military and civilian populations.